No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Zhejiang Cheng Yi Pharmaceutical (603811.SH): A total of 2.89% of shares have been repurchased.
On February 6, Glonghui reported that Zhejiang Cheng Yi Pharmaceutical (603811.SH) announced that as of January 31, 2025, the company has repurchased a total of 9,448,796 shares through centralized bidding, accounting for 2.89% of the company's total share capital, with a highest Fill Price of 8.36 yuan/share, a lowest Fill Price of 7.29 yuan/share, and a total amount of funds paid of 75,118,432.64 yuan (excluding transaction fees). This share repurchase complies with the relevant laws and regulations and the requirements of the share repurchase plan disclosed by the company.
Zhejiang Cheng Yi Pharmaceutical Passes TGA-GMP Certification for Two APIs
Zhejiang Cheng Yi Pharmaceutical (603811.SH): Obtained TGA-GMP certification from Australia.
On January 10, Gelonghui reported that Zhejiang Cheng Yi Pharmaceutical (603811.SH) announced that from April 29, 2024, to May 3, 2024, it underwent a remote inspection by the Therapeutic Goods Administration of Australia (hereinafter referred to as "TGA") for cGMP (current Good Manufacturing Practice). The scope of the inspection included Active Pharmaceutical Ingredients for Azathioprine and Mercaptopurine. Recently, Zhejiang Cheng Yi Pharmaceutical received written notification from TGA indicating that it has passed certification. Zhejiang Cheng Yi Pharmaceutical first obtained TGA certification in 2010, and this is the third time it has passed TGA certification. The Active Pharmaceutical Ingredient for Azathioprine is mainly used for immunity.
Zhejiang Cheng Yi Pharmaceutical (603811.SH): The calcitriol soft capsules have obtained the pharmaceutical registration certificate.
On January 2nd, Gelonghui reported that Zhejiang Cheng Yi Pharmaceutical (603811.SH) announced the receipt of the drug registration certificate for Calcifediol soft capsules approved by the National Medical Products Administration. Calcifediol soft capsules are clinically indicated for postmenopausal osteoporosis, chronic renal failure, especially for patients undergoing dialysis with renal osteodystrophy, postoperative hypoparathyroidism, idiopathic hypoparathyroidism, pseudohypoparathyroidism, vitamin D-dependent rickets, and hypophosphatemic vitamin D-resistant rickets, among others.
Zhejiang Cheng Yi Pharmaceutical (603811.SH): A total of 2.13% of shares have been repurchased.
On December 23, Gelonghui reported that Zhejiang Cheng Yi Pharmaceutical (603811.SH) announced that as of December 23, 2024, the company has repurchased a total of 6,960,220 shares through centralized bidding trading, accounting for 2.13% of the company's total share capital, an increase of 0.52% compared to the last disclosed figure, with a highest Fill Price of 8.36 yuan/share and a lowest Fill Price of 7.36 yuan/share, and a total amount of funds paid of 55,988,366 yuan (excluding transaction fees).
Benign Growth For Zhejiang Cheng Yi Pharmaceutical Co., Ltd. (SHSE:603811) Underpins Stock's 28% Plummet